Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital-Reference-Cited by-同舟云学术

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital

Published:2019-04-23 Issue:4 Volume:31 Page:370-377
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Sanz-Gil Roser¹,Pellicer Antonio²,Montesinos M. Carmen¹³^ORCID,Valcuende-Cavero Francisca⁴⁵

Affiliation:

1. Department of Pharmacology, Faculty of Pharmacy, Universitat de València, Valencia, Spain;

2. Department of Pharmacy, University Hospital La Plana, Castellón, Spain;

3. Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, Valencia, Spain;

4. Department of Dermatology, University Hospital La Plana, Castellón, Spain;

5. Pre-departmental Unit of Medicine, Universitat Jaume I, Castellón, Spain

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2019.1602246

Reference21 articles.

1. Use of topical antipsoriatic drugs in Denmark: a nationwide drug utilization study

2. Comparative Efficacy of Biologics in Psoriasis

3. Research gaps in psoriasis: Opportunities for future studies

4. Drug Survival Rates And Cost of Biological Agents for the Treatment of Moderate to Severe Psoriasis in the Balearic Islands (Spain)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose reduction of biologics in patients with plaque psoriasis: a review;Frontiers in Pharmacology;2024-03-28

2. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation;Clinical Drug Investigation;2023-07

3. National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure;Journal of Dermatological Treatment;2022-12-14

4. Persistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data;J DRUGS DERMATOL;2022

5. Dupilumab and tezepelumab in severe refractory asthma: new opportunities;Therapeutic Advances in Chronic Disease;2022-01